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Abstract. Nearly all bodily processes exhibit circadian rhythmicity. As a consequence, the pharmacoki-
netic and pharmacodynamic properties of a drug may also vary with time of day. The objective of this
study was to investigate diurnal variation in processes that regulate drug concentrations in the brain,
focusing on P-glycoprotein (P-gp). This efﬂux transporter limits the distribution of many drugs in the
brain. To this end, the exposure to the P-gp substrate quinidine was determined in the plasma and brain
tissue after intravenous administration in rats at six different time points over the 24-h period. Our results
indicate that time of administration signiﬁcantly affects the exposure to quinidine in the brain. Upon
inhibition of P-gp, exposure to quinidine in brain tissue is constant over the 24-h period. To gain more
insight into processes regulating brain concentrations, we used intracerebral microdialysis to determine
the concentration of quinidine in brain extracellular ﬂuid (ECF) and cerebrospinal ﬂuid (CSF) after
intravenous administration at two different time points. The data were analyzed by physiologically based
pharmacokinetic modeling using NONMEM. The model shows that the variation is due to higher activity
of P-gp-mediated transport from the deep brain compartment to the plasma compartment during the
active period. Furthermore, the analysis reveals that CSF ﬂux is higher in the resting period compared to
the active period. In conclusion, we show that the exposure to a P-gp substrate in the brain depends on
time of administration, thereby providing a new strategy for drug targeting to the brain.
KEY WORDS: blood–brain barrier; chronobiology; intrabrain distribution; microdialysis; PBPK
modeling.
INTRODUCTION
The treatment of brain tumors, infectious diseases, and
various neurological disorders is often unsuccessful because
the entry of most clinically available drugs into the brain is
restricted (1). This is due to a number of protective
mechanisms that prevent the distribution of potentially toxic
compounds in the brain but, at the same time, impede drugs
from reaching their target site in the central nervous system
(CNS). For example, several types of efﬂux transporters are
expressed in the brain, which expel a wide variety of
exogenous substances from the brain back into the
circulation (1,2).
A well-known efﬂux transporter in the CNS is P-
glycoprotein (P-gp). At the level of the blood–brain barrier
(BBB), it restricts the entry of many, mainly hydrophobic,
drugs to the brain (3). Although P-gp is mostly known for its
role in the efﬂux of its substrates at the BBB, it is also
expressed in blood–cerebrospinal ﬂuid (CSF) barrier
(BCSFB) as well as in parenchymal cells types, such as
astrocytes and pericytes (4). Several strategies have been
proposed to diminish P-gp-mediated efﬂux, but it has been
difﬁcult to implement these strategies in the clinic and,
especially, to apply them to chronic diseases (5).
The pharmacokinetic and pharmacodynamic properties
of a wide variety of drugs show diurnal variation, which is a
result of 24-h rhythms in, for example, gastrointestinal
function, activity of xenobiotic-metabolizing enzymes, blood
ﬂow, and glomerular ﬁltration rate (6). Consequently, thera-
peutic efﬁciency as well as the severity of side effects of drugs
may vary with time of day (7–9). Regarding P-gp, it has been
shown that its expression and activity show a diurnal rhythm
in the intestines of rodents, leading to different plasma
concentrations of orally administered P-gp substrates depend-
ing on the time of administration (10–15).
The objective of this study was to examine whether the
distribution of P-gp substrates in the CNS depends on time of
administration. Diurnal variation in P-gp activity could be
exploited to either increase or reduce the effect of P-gp on
Johanna H. Meijer and Elizabeth C.M. de Lange contributed equally
to this work.
Electronic supplementary material The online version of this article
(doi:10.1208/s12248-014-9625-4) contains supplementary material,
which is available to authorized users.
1 Division of Pharmacology, LACDR, Leiden University, PO Box
95022300 RA, Leiden, The Netherlands.
2 Laboratory for Neurophysiology, Department of Molecular Cell
Biology, Leiden University Medical Center, PO Box 9600 Mailbox
S5-P2300 RC, Leiden, The Netherlands.
3 To whom correspondence should be addressed. (e-mail:
J.H.Meijer@lumc.nl; ecmdelange@lacdr.leidenuniv.nl)
The AAPS Journal, Vol. 16, No. 5, September 2014 (# 2014)
DOI: 10.1208/s12248-014-9625-4
1029 1550-7416/14/0500-1029/0 # 2014 The Author(s). This article is published with open access at Springerlink.com
CNS target site distribution, depending on whether the aim is
to limit or enhance CNS distribution of the drug. Other
processes that govern CNS target site concentrations (16),
such as CSF turnover, may also vary over the course of the
day. Understanding the effect of time of administration on
CNS target site distribution may be useful to improve the
efﬁciency of therapies involving P-gp substrates.
In this study, the concentration of the P-gp substrate
quinidine was determined in plasma and brain tissue after
intravenous administration at six different time points over
the 24-h period in rats. As we observed a signiﬁcant 24-h
variation in P-gp-mediated drug transport in brain tissue, we
next used intracerebral microdialysis to obtain quinidine
concentration–time proﬁles in brain extracellular ﬂuid
(ECF) and in CSF at two different times of the day. Using
physiologically based pharmacokinetic (PBPK) modeling to
describe quinidine brain distribution (17), we were able to
explore differences in P-gp-mediated transport and CSF ﬂux
between the active and resting period of the animals. The
results show that time is an important consideration in the
design of drug treatments targeted at the CNS.
MATERIALS AND METHODS
Animals
Male Wistar rats (Charles River, The Netherlands) were
housed in groups under standard environmental conditions
(12:12LD cycle) with free access to water and food (SDS,
Technilab-BMI, Someren, the Netherlands). After surgery,
the rats were kept individually. All animal procedures were
performed in accordance with the Dutch law on animal
experimentation and were approved by the Animal Ethics
Committee of the Leiden University (protocol number
DEC12088).
Chemicals and Solutions
Quinidine, quinidine sulfate dehydrate, and quinine were
obtained from Sigma-Aldrich (Zwijndrecht, the Netherlands);
tariquidar from Xenova Group PLC (Cambridge, UK); saline
and 5% glucose in saline from the Leiden University Medical
Centre (Leiden, the Netherlands); Heparin from LEO
Pharma BV (Breda, the Netherlands); nembutal and
isoﬂurane from AUV (Cuijk, the Netherlands); phosphoric
acid and boric acid from Merck (Darmstadt, Germany),
sodium hydroxide and triethyl amine (TEA) from Baker
(Enschede, the Netherlands); and methanol, methyl tert-butyl
e ther (TBME), and acetoni t r i le f rom Biosolve
(Valkenswaard, the Netherlands). Perfusion ﬂuid (PF) for
microdialysis experiments was prepared as described in (18).
Surgery
Animals were anesthetized by isoﬂurane during surgical
procedures (induction, 5%; maintenance, 1–2%). A cannula
was inserted in the femoral artery and femoral vein 7 days
prior to the experiment as described previously (17). Animals
used for microdialysis experiments also received microdialysis
guides with dummy probes (CMA, Solna, Sweden) in the
caudate putamen (CP; coordinates from bregma, AP-
1.0 mm L+3.0 mm V-3.4 mm) and in the cisterna magna
(CM; coordinates from lambda, AP-2.51 mm L+2.04 mm V-
8.34 mm, at an angle of 25° anterior from the dorsoventral
axis and 11° lateral from the anteroposterior axis) (17).
Twenty-four hours before the experiment, the dummy probes
in CP and CM were replaced by 4 and 1 mm microdialysis
probes (CMA), respectively.
Drug Administration, Serial Blood Sampling, and Collection
of Brain Tissue
Brain distribution experiments were performed at six
different time points across the 24-h period; t=0 (start of
quinidine administration) was at Zeitgeber Time (ZT) 0, ZT4,
ZT8, ZT12, ZT16, or ZT20 (±10 min), with ZT12 deﬁned as
the moment of lights off. Microdialysis and in vivo recovery
experiments were performed with t=0 at ZT8 or ZT20. The
number of animals per group is shown in Supplemental
Table I. Between ZT12 and ZT0 experiments were conducted
in dim red light.
Animals were pretreated with an intravenous infusion of
vehicle (5% glucose in saline) or 15 mg/kg tariquidar in 5%
glucose at t=−25 min for 10 min at a rate of 500 μL/min/kg
with a syringe pump (Pump 22 Multiple Syringe Pump,
Harvard Apparatus, Holliston, MA, USA). In brain distribu-
tion and microdialysis experiments, quinidine (10 mg/kg) was
administered intravenously at t=0 in 10 min at a rate of
250 μL/min/kg. Blood samples (100 μL) were collected at t=
−10, 10, 30, 60, 90, 120, 150, 180, 210, and 240 min in
heparinized Eppendorf tubes and centrifuged for 10 min at
5,000 rpm (Eppendorf Microcentrifuge Model 5415D) to
obtain plasma. Plasma was stored at −20°C until analysis. At
t=240 min, the rats were sacriﬁced with an intravenous
injection of Nembutal and transcardially perfused with PBS
until the organs were free of blood. Brain tissue was removed
and stored at −80°C.
Intracerebral Microdialysis
Microdialysis probe inlets were connected to a syringe
ﬁlled with PF, and the outlets were connected to a fraction
collector (Univentor microsampler 820, Univentor Ltd,
Zejtun, Malta) with FEP tubing. Perfusion of the microdial-
ysis probes with a syringe pump (Bioanalytical Systems Inc.,
West Lafayette, USA) started 2 h prior to quinidine
administration. Perfusion rate was set to 1 μL/min. Samples
were collected every 20 min until t=240 min and stored at
−80°C.
In Vivo Retrodialysis
The recovery of quinidine into the microdialysis probe
was determined by in vivo retrodialysis. Probes were perfused
with blank PF for 2 hours, after which the concentration of
quinidine in PF was changed every 2 h from 20 to 50 ng/mL
and to 200 ng/mL. Samples were collected every 20 min at a
perfusion rate of 1 μL/min. The probe recovery (extraction
fraction) was calculated as described by Westerhout et al.
(2013). The extraction fractions from the probes located in
CP and CM were used to convert the measured
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microdialysate concentrations to ECF and CSF concentra-
tions, respectively.
Plasma Protein Binding
To determine the degree of plasma protein binding of
quinidine, 50 μL aliquots of each plasma sample taken at t=
30 min and t=90 min were pooled per experimental time
point (ZT) and pre-treatment (vehicle or TQD). The samples
were equilibrated at 37°C for 30 min, and 200 μL was added
to a pre-heated Centrifree 30 K ultraﬁltration device
(Millipore BV, Etten-Leur, the Netherlands). The samples
were centrifuged for 20 min at 5,000 rpm at 37°C according to
the manufacturer’s protocol. The unbound fraction of quin-
idine in plasma (funbound) was calculated by dividing the
concentration of the ultraﬁltrate by the concentration in the
unﬁltered sample.
Measurement of Quinidine Concentration in Microdialysate,
Plasma, and Brain Homogenates
Quinidine concentrations in plasma, microdialysates, and
brain homogenates were measured using high-performance
liquid chromatography (HPLC) with ﬂuorescence detection
as described earlier (19). Microdialysates (10 μL) were
directly injected into the HPLC system using a mobile phase
with an acetonitrile/buffer ratio of 17:83 (v/v). Brain tissue
was homogenized in 50-mM phosphate buffer (pH7.4) using
the Bullet Blender 5 (Next Advance Inc., NY, USA)
according to the manufacturer’s protocol. Brain homogenates
were diluted 6× (w/v) in 50-mM phosphate buffer (pH7.4).
Extraction of quinidine from plasma and brain homogenate
was performed as described earlier (19). The injection
volume was 2–20 μL depending on the type of sample. The
mobile phase consisted of acetonitrile and buffer in a ratio of
14:86 (v/v).
Data Analysis
Areas under the curve (AUC in ng/mL×min) of unbound
quinidine in plasma from 0 to 240 min after administration
(AUCPLu,0–240) were calculated using the trapezoidal rule.
Ratios between parameters were determined for each animal
individually before calculating the mean per group. The means
of two groups were compared by an unpaired Student’s t test
(normally distributed data) or a Mann–Whitney U test (not
normally distributed data). To compare the means of more than
two groups, an ANOVA (normally distributed data) or
Kruskal–Wallis test (not normally distributed data) was used.
Normal distribution was assessed by the Sharipo–Wilk test. p
values below 0.05 were considered signiﬁcant. Statistical analy-
ses and graphical visualization were performed with R version
2.14.1 or version 3.0.1 (R Foundation for Statistical Computing,
Vienna, Austria).
Physiologically Based Pharmacokinetic Modeling
PBPK brain distribution modeling was performed to
investigate the effect of time of administration on the
pharmacokinetics of quinidine in plasma, total brain, ECF,
and CSF quantitatively using a nonlinear mixed effect model
approach with NONMEM software version VII (GloboMax
LLC, Hanover, MD, USA). The PBPK model describing
brain distribution of quinidine that was previously published
(17) was applied to the data (Supplemental Figure 1). Data
obtained during the microdialysis experiments in this study
were added to the previously obtained data produced with
the same experimental method during the resting period of
the animals (17). Using covariate analysis, the effect of time
of administration was tested on parameters describing P-gp-
mediated transport and CSF ﬂux. Statistical signiﬁcance was
based on changes in the objective function value (OFV; p<
0.05). The difference in the OFV obtained by comparing
each model was assumed to be asymptotically chi-squared
distributed with degrees of freedom (df) equal to the
difference in the number of parameters between the two
models. Goodness-of-ﬁt plots (model predicted vs. observed
data values) were evaluated by diagnostic scatter plots. The
stability and performance of the ﬁnal model were conﬁrmed
by a visual predictive check on the simulated distribution of
the concentration data to cover over 90% of the observed
data.
RESULTS
Time of Administration Has No Effect on Plasma
Pharmacokinetics of Quinidine
We ﬁrst determined the mean concentration–time pro-
ﬁles of unbound quinidine in plasma after intravenous
administration at six experimental time points (ZT0-20)
(Fig. 1a). Unbound plasma concentrations were derived from
total plasma concentrations corrected for by the unbound
fraction in plasma (0.286±0.006). Total and unbound concen-
trations of quinidine in plasma showed a highly signiﬁcant
linear correlation (r2=0.953, N=24, p=0.000, Pearson’s
correlation; Supplemental Figure 2A). The unbound fraction
did not depend on time of administration (F(5,17)=2.52, p=
0.07, two-way ANOVA; Supplemental Figure 2B) and pre-
treatment with TQD (F(1,17)=1.70, p=0.21, two-way
ANOVA; Supplemental Figure 2C)
The unbound quinidine concentration in plasma in
vehicle-treated animals at t=30, 90, 120, 150, 210, and 240
was inﬂuenced by time of administration (p<0.05, one-way
ANOVA or Kruskal–Wallis, as appropriate; Fig. 1a). Time of
administration had no signiﬁcant effect on the area under the
time concentration curve of unbound quinidine in plasma
from 0 to 240 min after administration (AUCPLu(0–240))
(Fig. 1b F(5,34)=1.49, p=0.220, one-way ANOVA). These
results indicate that the total exposure to quinidine in plasma
is not affected by time of administration.
Quinidine Brain Tissue Concentration Shows Significant
Diurnal Variation
The concentration of quinidine in brain tissue at t=240
(CBR) relative to AUCPLu(0–240) was found to be signiﬁcantly
affected by time of administration (Fig. 1c H(5)=14.9, p=
0.011, Kruskal–Wallis test). In experiments conducted in the
resting period of the animals (i.e., animals treated at ZT0,
ZT4, and ZT8), the CBR: AUCPLu(0–240) was on average twice
as high compared to the ratio in the active period (at ZT12,
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ZT16, or ZT20). These results indicate that the exposure to
the P-gp substrate quinidine in the brain, relative to plasma
exposure, exhibits diurnal variation.
Diurnal Variation of Total Brain Quinidine Concentrations
is Due to the Variation in P-gp-Mediated Transport
To determine whether the effect of time of administration
on the exposure to quinidine in brain tissue is due to variation in
P-gp-mediated transport over the 24-h period, we administered
the selective P-gp inhibitor tariquidar intravenously 30min prior
to quinidine administration at ZT0, 4, 8, 12, 16, or 20. Time of
administration did not signiﬁcantly affect unbound plasma
concentrations of quinidine at any of the sampling points
(Fig. 2a) and had no effect on AUCPLu(0–240) (Fig. 2b F(5,33)=
0.635, p=0.675, one-way ANOVA) in tariquidar-treated ani-
mals, indicating that also in this group of animals, time of
administration does not affect exposure to quinidine in plasma.
Importantly, time of administration also did not signiﬁcantly
affect CBR: AUCPLu(0–240) of quinidine after tariquidar treat-
ment (Fig. 2c F(5,31)=1.28, p=0.297, one-way ANOVA).
Hence, tariquidar pre-treatment abolished the diurnal variation
in CBR: AUCPLu(0–240) that was observed in vehicle-treated
animals. These results indicate that the exposure to quinidine in
the brain relative to plasma levels exhibits diurnal variation
unless P-gp is inhibited.
Exposure to Quinidine in CNS is Inﬂuenced by Diurnal
Variation in P-gp Activity and CSF Flux
Next, we used intracerebral microdialysis to determine
unbound concentrations of quinidine in brain extracellular
ﬂuid (ECF) and cerebrospinal ﬂuid (CSF) from 0 to 240 min
after intravenous quinidine administration at ZT8 (resting
period) and ZT20 (active period of the animals). The
extraction fractions (4 mm probe, 13±1.4%; 1 mm probe,
8.4±2.6%) were used to calculate unbound concentrations in
ECF and CSF from microdialysate concentrations.
We calculated the mean concentration–time proﬁles of
unbound quinidine in plasma, ECF, and CSF (Fig. 3) as well as
CBR: AUCPLu(0–240) (Supplemental Figure 3B-C) at ZT8 and
ZT20 in vehicle- and TQD-treated animals. The fraction
unbound of quinidine in plasma (0.276±0.015) was not signiﬁ-
cantly different in these experiments compared to that observed
in the brain distribution experiments (t(29)=0.747, p=0.461,
two-sided t test, Supplemental Figure 2D). Also, AUCPLu(0–240)
and CBR: AUCPLu(0–240) measured in these experiments were
comparable to those obtained in brain distribution experiments
(Supplemental Figure 3). In vehicle-treated animals, ECF
concentrations were not signiﬁcantly affected by time of
administration at any of the sampling times (Fig. 3c), while
CSF concentrations were higher in the ﬁrst 100 min after
administration in the active period compared to the values
obtained after administration in the resting period (Fig. 3e). In
tariquidar-treated animals, time of administration signiﬁcantly
affectedECF concentrations at two sampling times (Fig. 3d), but
had no effect on CSF concentrations (Fig. 3f).
The data from the microdialysis experiments were ﬁtted
to a PBPK model that was previously used to describe
quinidine pharmacokinetics in plasma, ECF, CSF, and deep
brain tissue (17). We investigated the effect of time of
Fig. 1. Quinidine exposure in plasma and brain in vehicle-treated
animals. a Time–concentration proﬁles of unbound quinidine in
plasma. Different symbols represent the different experimental
time points (ZT0, 4, 8, 12, 16, and 20). Asterisks indicate
signiﬁcant effect of ZT on plasma concentration at the designated
sampling times (n=6–8 animals per group). b Area under the
curve for unbound quinidine in plasma from 0 to 240 min after
administration (AUCPLu,0–240) at different experimental time
points (n=5–8 animals per group). No signiﬁcant time of day
effect on AUCPLu,0–240 was found (p>0.05, one-way ANOVA). c
Quinidine concentration at t=240 min in brain homogenate
relative to plasma AUC (CBR:AUCPLu,0–240) at different experi-
mental time points (n=4–8 animals per group). Time of admin-
istration signiﬁcantly affects this ratio (p<0.05, Kruskal–Wallis
rank sum test). Mean ± SEM in all graphs. n.s. not signiﬁcant; *p
<0.05
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administration on the parameters describing P-gp-mediated
transport from the plasma compartment to and from deep
brain tissue, ECF and CSF, and on CSF ﬂux. Using covariate
analysis, we found that the model that takes into account the
effect of time of administration on both P-gp-mediated
transport and CSF ﬂux best described the data (Table I),
indicating that time of administration signiﬁcantly inﬂuences
P-gp-mediated transport and CSF ﬂux. The parameter
estimates of the model (Table II) show that the estimated P-
gp-mediated transport of quinidine from the deep brain
compartment to plasma is almost 2.9× higher during the
active period of the animals compared to the resting period
(659 vs 228 μL/min, Table II). Furthermore, CSF ﬂux is
almost twice as high during the resting period of the animals
compared to the active period (0.522 vs 0.227 μL/min,
Table II).
DISCUSSION
In this study, we show that the exposure to the P-gp
substrate quinidine in total brain tissue is subject to signiﬁcant
diurnal variation. This variation is abolished by pre-treatment
with the selective P-gp inhibitor tariquidar, indicating a
selective P-gp-mediated origin. The exposure to quinidine in
brain tissue is lower during the active period compared to the
resting period of the animals, which shows that the activity of
P-gp is elevated during the active period. PBPK modeling
based on plasma, ECF, CSF, and total brain concentrations of
quinidine after intravenous administration in the active and
resting period of the animals supports these ﬁndings by
showing that time of administration signiﬁcantly affects P-gp-
mediated transport as well as CSF ﬂux. Therefore, the
ﬁndings presented in this study show that the exposure to a
drug in the brain is affected by time of administration and
provides a mechanism that involves 24-h variation in the
activity of P-gp-mediated transport and CSF ﬂux.
Circadian rhythms are present in many bodily processes
and are controlled by a central clock located in the
hypothalamus (20). Rhythms in peripheral organs are syn-
chronized by the central clock, but are driven locally by an
intracellular translational–transcriptional feedback loop with
a period of approximately 24-h (21). This clock mechanism is
responsible for the circadian rhythm that is found in the
transcription, translation, and post-translational modiﬁcation
of many genes and their associated proteins (21). Our results
show that the distribution of quinidine in the brain depends
on time of administration due to variation in two processes.
Firstly, we ﬁnd that the estimated activity of P-gp-mediated
transport is higher during the active period of the animals
compared to the resting period. This is in line with several in
vitro and in vivo studies that have shown 24-h variation in the
expression and activity of P-gp in several different cell types
(10–15). For example, Okyar et al. (2012) found that the
activity of P-gp in the intestine is higher during the active
period of rats (13). Future studies investigating the activity of
P-gp in different cell types of the CNS across the 24-h cycle
may provide further information on the molecular mecha-
nisms underlying the ﬁndings presented in this study.
In addition to 24-h variation in P-gp activity, the
PBPK model (17) that was used to describe the effect of
time of administration on the pharmacokinetics of quini-
dine in the brain shows that CSF ﬂow is larger during the
Fig. 2. Quinidine exposure in plasma and brain in tariquidar-treated
animals. a Time–concentration proﬁles of unbound quinidine in
plasma. Different symbols represent the different experimental time
points (ZT0, 4, 8, 12, 16, or 20). No signiﬁcant effect of ZT was found
between plasma concentrations at different sampling times (n=6–8
animals per group). b Area under the curve for unbound quinidine in
plasma from 0 to 240 min after administration (AUCPLu,0–240) at
different experimental time points (n=5–8 animals per group). No
signiﬁcant time of day effect on AUCPLu,0–240 was found (p>0.05,
one-way ANOVA). c Quinidine concentration at t=240 min in brain
homogenate relative to plasma AUC (CBR:AUCPLu,0–240) at different
experimental time points (n=4–8 animals per group). No signiﬁcant
time of day effect was found on this ratio in tariquidar-treated
animals (p>0.05, one-way ANOVA). Mean ± SEM in all graphs. n.s.
not signiﬁcant
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resting period of the animals compared to the active period.
In line with these ﬁndings, a recent study showed that sleep
markedly increases CSF inﬂux, thereby facilitating the
removal of metabolic waste products from the CNS (22).
This process may also affect the distribution of peripherally
administered drugs in the brain. With the design used in this
study, we cannot exclude the possibility that the sleep/wake
state of the animal, rather than diurnal rhythmicity as such,
is responsible for the variation in CSF ﬂow or P-gp function
over the 24-h period.
The variation in P-gp activity over the 24-h cycle had a
much larger effect on quinidine concentrations in the brain
Fig. 3. Microdialysis experiments in vehicle- and TQD-treated animals. Time–concentration proﬁles of
unbound quinidine in plasma (a, b, n=7–8 animals/group), ECF (c, d, n=7–8 animals/group), and CSF (e, f,
n=6–8 animals/group) at ZT8 (open symbols) and ZT20 (closed symbols) in vehicle-treated animals (a, c,
e) and TQD-treated animals (b, d, f). Asterisks indicate signiﬁcant effect of ZT on quinidine concentration
at the designated sampling times (p<0.05, two-sided t test or Mann–Whitney U test). Mean ± SEM in all
graphs. *p<0.05
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Table I. Covariate Analysis
Covariate Change in OFVa p value
Time of administration (P-gp) −155.6 <0.05
Time of administration (QCSF) −37.7 <0.05
Time of administration (P-gp and QCSF) −190.5 <0.05
aChange in objective function value (OFV) after addition of the covariate on various parameters compared to the model that does not take
into account time of administration on any of the parameters
Table II. Parameter Estimates of the PBPK Model
Parameter Value RSE (%)
Estimates
CLE Passive 83.3 mL/min 10.3
+P-gp 52.7 mL/min 6.5
QPL-PER1 Passive 831 mL/min 9.6
QPL-PER2 Passive 93.5 mL/min 18.3
CLPL-Deep Brain Passive 982 μL/min 14.7
+P-gp NAa
CLDeep Brain-PL Passive 12.3 μL/min 19.8
+P-gp Resting period 228 μL/min 17.7
+P-gp Active period 659 μL/min 15.6
CLPL-ECF Passive 25.7 μL/min 12.5
+P-gp Resting period 17 μL/min 18.5
+P-gp Active period 18.3 μL/min 18.5
CLECF-PL Passive 4.63 μL/min 15.2
+P-gp Resting period 3.14 μL/min 36.3
+P-gp Active period 3.98 μL/min 48.0
CLPL-LV Passive 3.23 μL/min 19.9
+P-gp Resting period 1.55 μL/min 30.1
+P-gp Active period 2.44 μL/min 17.5
CLLV-PL Passive 0.513 μL/min 24.0
+P-gp NAa
CLPL-CM Passive 0.753 μL/min 23.5
+P-gp NAa
CLCM-PL Passive 1.02 μL/min 33.7
+P-gp NAa
QECF
b 0.2 μL/min
QCSF Resting period 0.522 μL/min 28.5
Active period 0.227 μL/min 36.0
VPL
b 10.6 mL
VPER
1 7.42 L 5.7
VPER
2 7.09 L 17.3
VDeep Brain
b 1440 μL
VECF
b 290 μL
VLV
b 50 μL
VTFV
b 50 μL
VCM
b 17 μL
VSAS
b 180 μL
Inter-individual variability
CLE 33.2% 17.2
Residual error
PL 42.8% 13.9
ECF 33.0% 13.9
LV 31.9% 18.7
CM 36.2% 13.8
Deep brain 35.6% 13.4
Objective function value 30,298.06
PER1 peripheral compartment 1, PER2 peripheral compartment 2, PL plasma, ECF brain extracellular ﬂuid, LV lateral ventricle, CM cisterna
magna, QECF ECF ﬂow, QCSF CSF ﬂow, V volume of distribution of the compartments, TFV third and fourth ventricle, SAS subarachnoid
space, +P-gp effect of P-gp-mediated transport on the parameter
a Parameter not available
b Physiological values derived from literature (17)
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tissue than in ECF. Total brain concentrations reﬂect the
concentration of quinidine in both ECF and intracellular ﬂuid
(ICF) of brain parenchymal cells. The relatively small
difference in the effect of P-gp on the clearance of quinidine
from ECF to plasma during the active and resting periods of
the animals cannot account for the large difference in the
effect of P-gp on the clearance of quinidine from brain tissue
to plasma. Therefore, we propose that an additional P-gp-
dependent barrier between the ECF or plasma and the ICF of
brain parenchymal cells gives rise to the observed variation.
The existence of an additional barrier that affects the
distribution of drugs in parenchymal cells has previously
been suggested by the observation that valproic acid, an
anticonvulsant drug, is subject to active efﬂux at the
parenchymal cell membrane (23). Although valproic acid is
not a P-gp substrate (24), Scism et al. (23) show that the
parenchymal cell membrane can play an important role in the
distribution of drugs in the brain. Furthermore, Syvänen et al.
(19) show that induction of status epilepticus in rats affects P-
gp activity at the level of the parenchyma rather than at the
BBB.
Several lines of evidence suggest that P-gp is present in
brain parenchymal cells, such as in pericytes and astrocytes
(4,25,26). P-gp does not seem to be present in neurons in the
healthy mammalian brain, but its expression is rapidly
induced when challenged, for example, by hypoxic stress or
the induction of status epilepticus (27,28). Importantly, it
should be kept in mind that experiments are generally
conducted during the resting period of the animals, which is
the time window during which P-gp activity is lowest
according to our ﬁndings. The existence of a barrier from
the ECF to the ICF is of special interest for drugs that have
an intracellular CNS target. Future studies should aim to
elucidate this process more clearly.
A question that needs to be addressed is to what extent a
twofold increase in total brain exposure is clinically relevant.
Several strategies have been proposed to minimize the effect
of P-gp on its substrates that are used as drugs to treat various
CNS disorders. For example, pharmacological inhibition of P-
gp by tariquidar in humans leads to a dose-dependent
increase in brain uptake of a P-gp substrate (29,30). At a
dose of 6 mg/kg, there is a fourfold increase in brain uptake of
radiolabeled loperamide (29). However, this dose requires
intravenous infusion for more than 1 h due to a hemolytic
effect of one the co-solvents (29,31). Another limitation
associated with P-gp inhibitors in humans is that the unbound
plasma concentrations are relatively low, which limits the
degree of P-gp inhibition (32). In light of these ﬁndings, the
more than twofold increase in brain exposure that was
observed in this study, by investigating a naturally occurring
physiological process, could therefore well be of clinical
relevance. This holds especially true for drugs with a narrow
therapeutic index in which a slight increase in brain concen-
tration leads to a large increase in effect size.
In summary, this study indicates that the exposure to a P-
gp substrate in the brain is subject to diurnal variation. Using
a selective and potent P-gp inhibitor, we are able to show that
this is due to variation of P-gp-mediated transport which is
markedly elevated during the active period of the animals
compared to the resting period. Furthermore, CSF ﬂux is
increased during the resting period, which may also cause
variations in the exposure to a drug in the brain. Importantly, these
ﬁndings emphasize the need to take into account the timing of
drug administration, both in clinical and experimental situations.
Dosing at the appropriate time of the day may be an effective
strategy to modulate the delivery of P-gp substrates to the brain.
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